CTOs on the Move

Clemson University Biomedical Engineering Innova

www.cucubeinc.com

 
The Clemson University Biomedical Engineering Innovation Campus develops high-impact medical technology and devices for disease management and technology transfer from bench to bedside.
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million
  • www.cucubeinc.com
  • 200 C Patewood Drive
    Greenville, SC USA 29615
  • Phone: 864.656.5557

Executives

Name Title Contact Details

Similar Companies

Green Point Research

Working to cultivate a better tomorrow by bringing together human, natural & financial resources to grow our businesses and communities.

Unlearn

Founded in 2017, Unlearn.AI brings together a world-class team of experts across pharma, physics, machine learning, and business who share a vision of pioneering AI to eliminate trial and error in medicine. Unlearn is the only company creating TwinRCTsTM, which combine AI, prognostic digital twins, and novel statistical methods to run clinical trials requiring fewer patients in the control arm. Unlearn`s technology is used by leading global pharmaceutical companies, including Merck KGaA, Darmstadt, Germany, and has been published in conference abstracts and scientific journals, including Scientific Reports - Nature and The International Journal of Biostatistics. The European Medicines Agency qualifies Unlearn`s PROCOVA™ procedure, which provides the regulatory framework for the application of TwinRCTs to Phase 2 and 3 clinical trials.

SomnoMedics

SomnoMedics, LLC is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Surrozen

Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway.

Mesoblast

Mesoblast is a world leader in developing innovative cellular medicines. We have established what we believe is the industry`s most clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. All our clinical programs target significant, under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions.